

In the Claims:

1. (Currently Amended) An isolated immunogenic polypeptide comprising a ~~sequence selected from the group consisting of~~ residues 26 to 186 of SEQ ID NO: 29 ~~23 to 45, and 55.~~

A'
2. (Currently Amended) The isolated immunogenic polypeptide of claim 1 further comprising about the N-terminal two thirds of ~~the sequences selected from~~ SEQ ID NO: 29 ~~23 to 45, and 55.~~

3. (Currently Amended) The isolated immunogenic polypeptide of claim 1 wherein said polypeptide comprises ~~has an amino acid sequence selected from the group consisting of~~ SEQ ID NO: 29 ~~23 to 45, and 55.~~

4 - 9 (Withdrawn)

10. (Original) A vaccine composition comprising an immunogenically effective amount of an immunogenic polypeptide of claims 1, 2, or 3, wherein said immunogenic polypeptide is in a pharmacologically acceptable carrier.

11 - 38 (Withdrawn)